TLS data
 

BioCommunique

Corporate Newsletter

 
 
Biocom’s Los Angeles Executive Director Dina Lozofsky participated on panel at Supervisor Mark Ridley-Thomas’ first ever invite-only economic forum.

Supervisor Mark Ridley-Thomas Convenes LA Area Economic Panel, Including Biocom Staff

  • Thu Oct 05 19:54:00 GMT 2017
  • Los Angeles
  • Author Melanie Cohn

On September 22nd, Biocom’s Los Angeles Executive Director Dina Lozofsky participated on a panel of speakers at Supervisor Mark Ridley-Thomas’ first ever invite-only economic forum. Dina spoke to Los Angeles area elected officials and government staff, academia, business associations, and private sector participants about the importance of the life science industry in Los Angeles and its impact on the local economy.

Supervisor Ridley-Thomas convened economic development leadership from his second district (including City of Los Angeles, Carson, Compton, Culver City, Gardena, Inglewood, Lawndale, and Lynwood) to discuss fostering innovation and growing key clusters across the district. Other panelists included Michael Grimshaw, Director of the Entrepreneurial Institute at Cal State Dominguez Hills, Jose Gonzales, Chief Diversity Officer at Media Health Technologies, and Praveen Penmetsa, CEO of Motivo Engineering. Panelists addressed how to further economic activity and job growth through increased knowledge sharing and collaboration across the region, and the role of the public sector in supporting innovation.

 
 

Stay in the know with the Biocommunique

Sign up for Biocom's bi-weekly newsletter to get all the latest life science news sent directly to your inbox.

 
 

Related Articles View All

https://www.biocom.org/servlet/servlet.ImageServer?id=0155A0000096S5NQAU&oid=00DA0000000Kz7JMAS  
Biocom CEO cited Fletcher's record of unprecedented accomplishment working with the life science industry.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A0000096RbzQAE&oid=00DA0000000Kz7JMAS  
SB 1121, a "clean-up" bill to AB 375, contains the concerns of Biocom and others centered around a provision which affects HIPAA.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A0000096RbfQAE&oid=00DA0000000Kz7JMAS  
Although Biocom remained opposed to the bill, the provisions set forth will not place unreasonable burden on manufacturers and allows them flexibility to meet mandates.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A0000096RQIQA2&oid=00DA0000000Kz7JMAS  
The new Private Payor Program allows manufacturers to receive feedback from the FDA, giving them the opportunity to develop a clear evidence generation strategy.